Yoshifumi Saisho, MD, PhD
- Director, Saisho Diabetes Clinic, Tokyo, Japan
- Adjunct Professor, Keio University School of Medicine, Tokyo, Japan
- Adjunct Clinical Professor, Kyorin University School of Medicine, Tokyo, Japan
- Academic Councilor, Japan Diabetes Society
- Board member, International Society of Personalized Medicine
- Board member, Certification Board for Diabetes Educators in Japan
- Editorial board, Diabetes Research and Clinical Practice
- Editorial board, Diabetes, Obesity and Metabolism
- Editorial board, BMC endocrine disorders
Biography
Dr. Saisho received his medical degree in 1998 and his PhD degree in 2009, both from the Keio University School of Medicine in Tokyo. Before obtaining his current position as assistant professor, Dr. Saisho completed a three-year postdoctoral fellowship at the Larry L. Hillblom Islet Research Center at the University of California-Los Angeles’s David Geffen School of Medicine (Prof. Peter C. Butler). Dr. Saisho’s area of interest is Diabetology, especially beta cell dysfunction in diabetes. Dr. Saisho is the author or coauthor of more than 100 publications.
How does your research relate to the SDGs?
Prevention is a key to “well-being”. Type 2 diabetes is a progressive disease, with decline in beta cell function. Since impairment of beta cell function started more than 10 years before the development of hyperglycemia, earlier intervention for type 2 diabetes is critical to preserve beta cell function. Having that beta cell expansion in response to obesity in humans is limited, insulin resistance inevitably leads to an increment in beta cell workload, even before the onset of diabetes. Longstanding overwork of beta cell results in beta cell malfunction, and eventually beta cell death, like “Karoshi” in Japanese. Once the number of beta cells starts to decrease, the rest of beta cells must work harder to maintain normoglycemia, forming the vicious cycle. Therefore, the lifestyle modification including healthy eating and physical activity should direct towards the reduction in beta cell workload, and protection of beta cell will be the path to the prevention of diabetes, as well as achievement of the SDGs.
- Beyond glucose: A beta-cell centric approach to prevent type 2 diabetes (https://www.youtube.com/watch?v=tPE66_w7uR4)
Why did you decide to go into your field of research?
In Japan, there are many patients with type 2 diabetes without obesity. Moreover, despite lifestyle modification, diabetes cannot be cured in most patients. Based on these facts, I hypothesized that beta cell dysfunction is the key to explore the pathogenesis of type 2 diabetes.
How has knowledge of topic developed over the course of your career?
I conducted my research at UCLA (Prof. Peter C Butler) between 2006 and 2009 as a postdoctoral fellow. This experience gave me the opportunity to develop my career thereafter.
What are your hopes for progress in the future?
Based on the beta cell centric concept of diabetes which we proposed, medical staffs and patients with type 2 diabetes should work together to protect beta cell. The beta cell centric concept will empower the people with type 2 diabetes, diminish the stigma, and enhance the advocacy among the people with type 2 diabetes.
Follow the Topic
-
BMC Endocrine Disorders
This is an open access, peer-reviewed journal that considers articles on the characterization, prevention, diagnosis and treatment of endocrine disorders.
Related Collections
With Collections, you can get published faster and increase your visibility.
Incretin-based therapies for cardiometabolic disease: mechanisms and clinical outcome
BMC Endocrine Disorders is calling for submissions to our Collection, Incretin-based therapies for cardiometabolic disease: mechanisms and clinical outcome.
Incretin-based therapies, particularly glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dual GLP-1/ Glucose-dependent Insulinotropic Polypeptide (GIP) receptor agonists have emerged as pivotal treatments in managing type 2 diabetes (T2D) and its associated cardiometabolic complications. These therapies leverage the physiological effects of endogenous incretins, modulating insulin and glucagon secretion and promoting satiety and contributing to superior glycemic control and weight management. As the prevalence of T2D and atherosclerotic cardiovascular disease (ASCVD) continues to rise globally, understanding the underlying mechanisms and clinical outcomes of these therapies is crucial for optimizing patient care.
Research in incretin-based therapies has made significant strides, demonstrating not only their effectiveness in lowering hemoglobin A1c (HbA1c), but also expanding more broadly into cardiovascular and metabolic benefits. Recent studies have revealed that GLP-1 RAs can reduce the risk of major cardiovascular events in higher risk populations, highlighting their role beyond traditional glucose control. Additionally, ongoing investigations into the molecular mechanisms of action may provide insights into novel therapeutic targets and inform personalized treatment strategies, ultimately improving patient outcomes in cardiometabolic disease.
As research in incretin-based therapies progresses, with further novel drugs in development leveraging GLP-1 as a backbone, we can anticipate further advancements that may enhance their efficacy and broaden their applications. Future studies may uncover new combinations of incretin therapies with other treatment modalities, providing synergistic effects for glycemic control and cardiovascular health. Moreover, a deeper understanding of patient-specific responses may lead to tailored therapies that maximize benefits while minimizing adverse effects, thereby revolutionizing the management of type 2 diabetes and its complications.
Topics may include, but are not limited to:
- Effects of GLP-1 RAs on cardiovascular and broader metabolic outcomes
- Comparative efficacy of GLP-1 RA and dual GLP-1/ GIP RAs
- Mechanisms underlying incretin therapy benefits
- Role of incretin therapy in weight management
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
This is a Sister Collection with Cardiovascular Diabetology.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jan 18, 2027
PCOS and reproductive health
BMC Endocrine Disorders is calling for submissions to our Collection, PCOS and reproductive health.
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age, characterized by a range of symptoms including menstrual irregularities, hirsutism, and anovulation. This condition not only impacts reproductive health but is also associated with long-term metabolic and psychological consequences, including infertility and increased risks for type 2 diabetes, cardiovascular disease, and certain cancers. Understanding the complexities of PCOS is essential for developing effective treatment strategies and improving the quality of life for those affected.
The significance of research in PCOS and reproductive health has gained momentum with recent advances in the understanding of the pathophysiology of the disorder. Improved diagnostic criteria and the exploration of lifestyle interventions have shown promise in managing symptoms and enhancing reproductive outcomes. Furthermore, ongoing studies are revealing the interconnectedness of PCOS with other health issues, such as insulin resistance and menopause, underscoring the need for a comprehensive approach to treatment and management.
As research continues to evolve, we may see innovative therapeutic strategies and personalized approaches tailored to individual patient needs. Enhanced understanding of the genetic and environmental factors contributing to PCOS could lead to early interventions that prevent the onset of associated comorbidities. Additionally, future advancements may focus on integrating mental health support into the management of PCOS, acknowledging the holistic nature of reproductive health.
Topics that are welcome include, but are not limited to, the following:
Impact of PCOS on fertility
Menstrual irregularities and PCOS
Hirsutism and management options
Long-term health risks associated with PCOS
Psychological aspects of living with PCOS
This Collection supports and amplifies research related to SDG 3: Good Health & Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jul 30, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in